This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...